In contrast, TERT genetic alterations, which occur in around 55% of all PTs and include TERT promoter hotspot mutations and rare TERT gene amplification, are more frequent in malignant tumors (Piscuoglio et al., 2016b). This evidence concerns the gene TERT and cancer.